SG11202101821TA - a2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA - Google Patents
a2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEAInfo
- Publication number
- SG11202101821TA SG11202101821TA SG11202101821TA SG11202101821TA SG11202101821TA SG 11202101821T A SG11202101821T A SG 11202101821TA SG 11202101821T A SG11202101821T A SG 11202101821TA SG 11202101821T A SG11202101821T A SG 11202101821TA SG 11202101821T A SG11202101821T A SG 11202101821TA
- Authority
- SG
- Singapore
- Prior art keywords
- antagonists
- alpha
- treatment
- sleep apnea
- adrenoceptor subtype
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18196686 | 2018-09-25 | ||
| PCT/EP2019/075102 WO2020064479A1 (en) | 2018-09-25 | 2019-09-19 | α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202101821TA true SG11202101821TA (en) | 2021-03-30 |
Family
ID=63685606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202101821TA SG11202101821TA (en) | 2018-09-25 | 2019-09-19 | a2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20210338662A1 (en) |
| EP (1) | EP3856183A1 (en) |
| JP (1) | JP2022502374A (en) |
| KR (1) | KR20210065948A (en) |
| CN (1) | CN112714647A (en) |
| AU (1) | AU2019350264A1 (en) |
| BR (1) | BR112021003340A2 (en) |
| CA (1) | CA3113700A1 (en) |
| CL (1) | CL2021000707A1 (en) |
| EA (1) | EA202190842A1 (en) |
| IL (1) | IL281645A (en) |
| JO (1) | JOP20210059A1 (en) |
| MA (1) | MA53711A (en) |
| MX (1) | MX2021003428A (en) |
| SG (1) | SG11202101821TA (en) |
| TW (1) | TW202034920A (en) |
| UA (1) | UA128095C2 (en) |
| WO (1) | WO2020064479A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020225185A1 (en) * | 2019-05-09 | 2020-11-12 | Bayer Aktiengesellschaft | COMBINATION OF AN α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA |
| WO2023118098A1 (en) * | 2021-12-22 | 2023-06-29 | Bayer Aktiengesellschaft | COMBINATION OF AN α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA |
| WO2023131638A1 (en) * | 2022-01-07 | 2023-07-13 | Bayer Aktiengesellschaft | 2,3-dihydrobenzo [b][1, 4]dioxin-2-ylmethyl)piperazin-1-yl derivates for the treatment of sleep apnea |
| WO2023249924A1 (en) * | 2022-06-21 | 2023-12-28 | Apnimed, Inc. (Delaware) | Methods of treating sleep apnea with a combination of a cannabinoid and a carbonic anhydrase inhibitor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7103449A (en) * | 1971-03-15 | 1972-09-19 | ||
| TW201024282A (en) | 2008-11-20 | 2010-07-01 | Orion Corp | New pharmaceutical compounds |
| US20180235934A1 (en) * | 2015-08-18 | 2018-08-23 | Massachusetts Institute Of Technology | Noradrenergic drug treatment of obstructive sleep apnea |
-
2019
- 2019-09-19 CA CA3113700A patent/CA3113700A1/en active Pending
- 2019-09-19 AU AU2019350264A patent/AU2019350264A1/en active Pending
- 2019-09-19 JP JP2021516568A patent/JP2022502374A/en active Pending
- 2019-09-19 SG SG11202101821TA patent/SG11202101821TA/en unknown
- 2019-09-19 EA EA202190842A patent/EA202190842A1/en unknown
- 2019-09-19 MA MA053711A patent/MA53711A/en unknown
- 2019-09-19 JO JOP/2021/0059A patent/JOP20210059A1/en unknown
- 2019-09-19 UA UAA202102170A patent/UA128095C2/en unknown
- 2019-09-19 CN CN201980061267.2A patent/CN112714647A/en active Pending
- 2019-09-19 US US17/279,536 patent/US20210338662A1/en active Pending
- 2019-09-19 EP EP19769177.7A patent/EP3856183A1/en active Pending
- 2019-09-19 WO PCT/EP2019/075102 patent/WO2020064479A1/en unknown
- 2019-09-19 MX MX2021003428A patent/MX2021003428A/en unknown
- 2019-09-19 BR BR112021003340-8A patent/BR112021003340A2/en unknown
- 2019-09-19 KR KR1020217008388A patent/KR20210065948A/en unknown
- 2019-09-23 TW TW108134163A patent/TW202034920A/en unknown
-
2021
- 2021-03-18 IL IL281645A patent/IL281645A/en unknown
- 2021-03-22 CL CL2021000707A patent/CL2021000707A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN112714647A (en) | 2021-04-27 |
| MA53711A (en) | 2021-12-29 |
| MX2021003428A (en) | 2021-06-15 |
| BR112021003340A2 (en) | 2021-05-11 |
| AU2019350264A1 (en) | 2021-03-25 |
| EP3856183A1 (en) | 2021-08-04 |
| CL2021000707A1 (en) | 2021-08-20 |
| US20210338662A1 (en) | 2021-11-04 |
| IL281645A (en) | 2021-05-31 |
| EA202190842A1 (en) | 2021-07-02 |
| CA3113700A1 (en) | 2020-04-02 |
| KR20210065948A (en) | 2021-06-04 |
| JOP20210059A1 (en) | 2023-01-30 |
| WO2020064479A1 (en) | 2020-04-02 |
| TW202034920A (en) | 2020-10-01 |
| JP2022502374A (en) | 2022-01-11 |
| UA128095C2 (en) | 2024-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202101821TA (en) | a2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | |
| SI3230298T1 (en) | 3-substituted 5-amino-6h-thiazolo(4,5-d)pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection | |
| EP3852735A4 (en) | Farnesoid x receptor agonists for the treatment of disease | |
| IL279260A (en) | Kdm1a inhibitors for the treatment of disease | |
| IL285782A (en) | Compounds, compositions, and methods for the treatment of disease | |
| GB201820450D0 (en) | Compound and its use for the treatment of alpha1-antitryspin deficiency | |
| GB202106894D0 (en) | Process for the preparation of 3alpha-hydroxy-5#LPHA-Pregnan-20-one (brexanolone) | |
| EP3866736A4 (en) | Methods and devices for treating sleep apnea | |
| EP3747888A4 (en) | Nitrogenated heterocyclic amide compound, and use thereof for medical purposes | |
| EP3405211A4 (en) | Oral octreotide for the treatment of disease | |
| IL291735A (en) | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases | |
| IL285452A (en) | New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine | |
| HK1258115A1 (en) | Crystalline forms of n-[(3-amino-3-oxetanyl)methyl]-2-(2,3-dihydro-1,1 -dioxido-1,4-benzothiazepin-4(5 h)-yl)-6-methyl-4-quinazolinamine for the treatment of respiratory syncytial virus (rsv) infections | |
| EP3619204A4 (en) | Compounds for the treatment of respiratory diseases | |
| EP3814375A4 (en) | Antibodies for the treatment of synucleinopathies and neuroinflammation | |
| IL261984B (en) | Sultiame for the treatment of sleep apnea | |
| EP3877382A4 (en) | Novel compounds for the treatment of respiratory diseases | |
| EP3820477A4 (en) | Compounds, compositions, and methods for the treatment of disease | |
| IL283183A (en) | A2-adrenoceptor subtype c (alpha-2c) antagonists for the treatment of sleep apnea | |
| IL284046A (en) | Treatment of respiratory disorders with arachidonate15-lipoxygenase (alox15) inhibitors | |
| ZA202104253B (en) | Medical fastening device for the fastening of grafts | |
| IL286000A (en) | Esketamine for the treatment of depression | |
| EP3807254A4 (en) | Heterocyclic compounds useful in the treatment of disease | |
| EP3720351A4 (en) | Methods and systems for the treatment of sleep apnea | |
| PL3618806T3 (en) | Compositon for the treatment of aphthas and mouth ulcers |